429 related articles for article (PubMed ID: 9108425)
41. Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia.
Bacigalupo A; Van Lint MT; Valbonesi M; Lercari G; Carlier P; Lamparelli T; Gualandi F; Occhini D; Bregante S; Valeriani A; Piaggio G; Pitto A; Benvenuto F; Figari O; De Stefano G; Caimo A; Sessarego M
Blood; 1996 Jul; 88(1):353-7. PubMed ID: 8704195
[TBL] [Abstract][Full Text] [Related]
42. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
Michel G; Leverger G; Leblanc T; Nelken B; Baruchel A; Landman-Parker J; Thuret I; Bergeron C; Bordigoni P; Esperou-Bourdeau H; Perel Y; Vannier JP; Schaison G
Bone Marrow Transplant; 1996 Feb; 17(2):191-6. PubMed ID: 8640165
[TBL] [Abstract][Full Text] [Related]
43. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation.
Van Lint MT; Uderzo C; Locasciulli A; Majolino I; Scimé R; Locatelli F; Giorgiani G; Arcese W; Iori AP; Falda M; Bosi A; Miniero R; Alessandrino P; Dini G; Rotoli B; Bacigalupo A
Blood; 1998 Oct; 92(7):2288-93. PubMed ID: 9746766
[TBL] [Abstract][Full Text] [Related]
44. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial.
Nimer SD; Giorgi J; Gajewski JL; Ku N; Schiller GJ; Lee K; Territo M; Ho W; Feig S; Selch M
Transplantation; 1994 Jan; 57(1):82-7. PubMed ID: 8291119
[TBL] [Abstract][Full Text] [Related]
45. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia.
Elmaagacli AH; Basoglu S; Peceny R; Trenschel R; Ottinger H; Lollert A; Runde V; Grosse-Wilde H; Beelen DW; Schaefer UW
Blood; 2002 Feb; 99(4):1130-5. PubMed ID: 11830457
[TBL] [Abstract][Full Text] [Related]
46. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
[TBL] [Abstract][Full Text] [Related]
47. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
[TBL] [Abstract][Full Text] [Related]
48. Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia.
Aversa F; Terenzi A; Carotti A; Felicini R; Jacucci R; Zei T; Latini P; Aristei C; Santucci A; Martelli MP; Cunningham I; Reisner Y; Martelli MF
J Clin Oncol; 1999 May; 17(5):1545-50. PubMed ID: 10334542
[TBL] [Abstract][Full Text] [Related]
49. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow.
Filipovich AH; Vallera DA; Youle RJ; Haake R; Blazar BR; Arthur D; Neville DM; Ramsay NK; McGlave P; Kersey JH
Transplantation; 1987 Jul; 44(1):62-9. PubMed ID: 3299923
[TBL] [Abstract][Full Text] [Related]
50. CD31 mismatching affects marrow transplantation outcome.
Grumet FC; Hiraki DD; Brown BWM ; Zehnder JL; Zacks ES; Draksharapu A; Parnes J; Negrin RS
Biol Blood Marrow Transplant; 2001; 7(9):503-12. PubMed ID: 11669217
[TBL] [Abstract][Full Text] [Related]
51. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
Pawson R; Potter MN; Theocharous P; Lawler M; Garg M; Yin JA; Rezvani K; Craddock C; Rassam S; Prentice HG
Br J Haematol; 2001 Dec; 115(3):622-9. PubMed ID: 11736947
[TBL] [Abstract][Full Text] [Related]
52. Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy: a Société Française de Greffe de Moelle study.
Bordigoni P; Esperou H; Souillet G; Pico J; Michel G; Lacour B; Reiffers J; Sadoun A; Rohrlich P; Jouet JP; Milpied N; Lutz P; Plouvier E; Cornu G; Vannier JP; Gandemer V; Rubie H; Gratecos N; Leverger G; Stephan JL; Boutard P; Vernant JP
Br J Haematol; 1998 Aug; 102(3):656-65. PubMed ID: 9722290
[TBL] [Abstract][Full Text] [Related]
53. Use of partially mismatched related donors extends access to allogeneic marrow transplant.
Henslee-Downey PJ; Abhyankar SH; Parrish RS; Pati AR; Godder KT; Neglia WJ; Goon-Johnson KS; Geier SS; Lee CG; Gee AP
Blood; 1997 May; 89(10):3864-72. PubMed ID: 9160695
[TBL] [Abstract][Full Text] [Related]
54. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
55. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival.
Doney K; Fisher LD; Appelbaum FR; Buckner CD; Storb R; Singer J; Fefer A; Anasetti C; Beatty P; Bensinger W
Bone Marrow Transplant; 1991 Jun; 7(6):453-9. PubMed ID: 1873592
[TBL] [Abstract][Full Text] [Related]
56. Tolerance in DLA-haploidentical canine littermates following CD6-depleted marrow transplantation and donor lymphocyte transfusion.
Zorn J; Herber M; Schwamberger S; Panzer W; Adler H; Kolb HJ
Exp Hematol; 2009 Aug; 37(8):998-1006. PubMed ID: 19446000
[TBL] [Abstract][Full Text] [Related]
57. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
58. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
[TBL] [Abstract][Full Text] [Related]
59. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT).
Ringdén O; Hermans J; Labopin M; Apperley J; Gorin NC; Gratwohl A
Leuk Lymphoma; 1996 Dec; 24(1-2):71-9. PubMed ID: 9049963
[TBL] [Abstract][Full Text] [Related]
60. Treatment of leukemia with partially matched related bone marrow transplantation.
Munn RK; Henslee-Downey PJ; Romond EH; Marciniak EJ; Fleming DR; Messino MJ; Macdonald JS; Rayens MK; Harder EJ; Phillips GL; Thompson JS
Bone Marrow Transplant; 1997 Mar; 19(5):421-7. PubMed ID: 9052906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
